Osteosarcoma is a common type of bone cancer that is developed in cells that are responsible for the formation of bones. In exceedingly rare conditions osteosarcoma occurs in the soft tissue outside the bones. Generally, it mostly occurs in teenagers, young adults, and older adult population.
Osteosarcoma Market is expected to register a CAGR of 6.09% to reach USD 791.08 Million by 2025.
The Global Osteosarcoma Market is emerging due to the high incidence of osteosarcoma. For instance, the prevalence of primary bone cancer is increasing across the world. According to the National Institutes of Health (NIH), an estimate of around 3,450 new cases of primary bone cancer was registered in 2018 in the US. A high number of incidences of osteosarcoma would support the growth of the market. According to the American Cancer Society, around 800 to 900 new cases of osteosarcoma are diagnosed in the US each year. The incidence of osteosarcoma is found to be high in adolescents and the geriatric population. Similarly, according to an article published in the North American Association of Central Cancer Registries, about 3,809 incident cases of osteosarcoma were identified in patients aged 40 years or older in 2018.
Request Sample Report at: https://www.reportocean.com/industry-verticals/sample-request?report_id=MRF182
Moreover, the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program estimated the incident rate of 4.4 cases per 1 million people below the age of 24 years in the US each year. This cumulative prevalence of osteosarcoma along with the rising geriatric population are driving the global osteosarcoma market.
Segmentation Overview of the Global Osteosarcoma Market
The global Osteosarcoma market is categorized into various segments. These major market segments are further categorized into various sub-segments to study the market in detail. The segmentation study offers detailed market study considering various growth determinants and geographical dynamics.
Global Osteosarcoma Market, by Type
Global Osteosarcoma Market, by Diagnosis & Treatment
Global Osteosarcoma Market, by End User
Regional Overview of the Global Osteosarcoma Market
The Global Osteosarcoma Market is broadly segmented based on region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas represent a market share of 40.02% in the year 2018. Americas is sub-segmented into North America and South America. North America has been further sub-segmented into the US and Canada.
Europe was the second-largest global osteosarcoma market in the year 2018. The Europe region is even more segmented into Western Europe and Eastern Europe. Western Europe, on the basis of countries, has been divided into the Germany, the UK, France, Italy, Spain, and the rest of Western Europe.
The Asia-Pacific region was classified as China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. It holds the third-largest position in the osteosarcoma market.
The market in the Middle East & Africa is likely to show minimum growth by factors such as limited access to and higher availability of treatment facilities. However, the high prevalence of bone cancer population will support growth of the market in the region during the forecast period.
The Prominent Players in the Global Osteosarcoma Market Pfizer Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Baxter, Novartis AG, Aurobindo Pharma, Hikma Pharmaceuticals PLC, Mylan N.V., and ADVAXIS, INC. The players operating in the global osteosarcoma market are focusing on product launches, along with expanding their global footprints by entering untapped markets.
Enquire before purchasing this report – https://www.reportocean.com/industry-verticals/sample-request?report_id=MRF182